The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.05
Bid: 3.00
Ask: 3.10
Change: 0.00 (0.00%)
Spread: 0.10 (3.333%)
Open: 3.05
High: 3.05
Low: 3.05
Prev. Close: 3.05
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: InnovaDerma sees profit return; ValiRx amends licence

Mon, 20th Dec 2021 15:00

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

FireAngel Safety Technology Group PLC - Coventry, England-based fire safety firm - Confirms it remains on target to meet market expectations for adjusted loss before tax for 2021, representing a "significant improvement" on 2020. However, it expects revenue to be at the lower end of market expectations. Additionally, debt at year end is expected to be ahead of earlier forecasts. Highlights supply chain issues have continued to intensify during the second half of 2021, with rising costs and component shortages affecting the group's ability to build products and increase stock inventory to meet growing demand. FireAngel Executive Chair John Conoley comments: "The board is pleased that despite severe headwinds, the company is on track to deliver an improved financial performance in 2021 and to have sufficient working capital for its forecasted needs."

----------

ValiRx PLC - Nuneaton, England-based drug development company - Amends license deal with Cancer Research Technology to enable a range of sub-licensing options. The updated VAL201 license restates the terms of the agreement, including the payment schedule and terms for milestones, the expected development plan and provides additional flexibility to a sub-licensee. Additionally, under the new terms CRT is required to formally approve any sub-license which ValiRx enters into relating to VAL201. CRT has also now approved the terms of the sub-license between pharmaceutical consultant TheoremRx and ValiRx and consented for the transaction to proceed in due course. ValiRx Chief Executive Suzy Dilly comments: "This amendment updates the VAL201 license terms in a manner that aligns the license with of the proposed terms of the sub-license between ValiRx and TheoremRx."

----------

InnovaDerma PLC - London-based developer of beauty, personal care and life science products - Posts narrowed operating pretax loss and expects a return to profitability in financial 2022. For the financial year that ended June 30, revenue is GBP10.2 million, down 23% from GBP13.2 million the year before, and operating loss narrows to GBP1.9 million from GBP5.0 million. Highlights a change in strategy, shifting focus away from revenue generation at the expense of profits to an "e-commerce led business to generate sustainable profitable growth". "The board is optimistic that the transformation plan enacted this year, as well as underlying improved consumer consumption versus last year, will enable the business to return to profitability this year. The group has been trading in line with expectations, with retail momentum steadily returning in the UK beauty category to pre-pandemic levels," Innovaderma says.

----------

Capital Metals PLC - London-based mineral sands explorer - Suffers a USD1.2 million pretax loss for the first half ended September 30, widened from a USD354,000 loss a year before. The company is not yet revenue generating. States it is focused on securing first industrial mining license at the Eastern Minerals Project in Sri Lanka, expects to receive this in the first quarter of 2022. Chair Greg Martyr comments: "This has been a transformational period for Capital Metals culminating in the award of our environmental impact assessment permit on 22 November 2021, despite the significant difficulties experienced in Sri Lanka during the Covid-19 pandemic. The obtaining of the EIA demonstrates the Sri Lankan authorities' support for the project and should enable us to meet our target of commencing commercial production in less than 12 months' time."

----------

Sportech PLC - London-based betting technology company - Extends period of exclusivity for discussions on the sale of its terrestrial lottery supply contract until December 1. Emphasises that there is no certainty that the sale will proceed.

----------

Voyager Life PLC - Perth, Scotland-based hemp seed oil products supplier - Buys CBD skincare firms Cannafull and Ascend Skincare for a total of GBP9,000. The parent company of Cannafull and Ascend Skincare, Cannafull Ltd, has recently gone into liquidation and consequently Voyager's acquisition of the two brands has been made from the liquidator. The GBP9,000 price tag will be for the brands, their websites and social media platforms, all fixtures and fittings and remaining inventory. Voyager is not however buying the parent company or taking on any liabilities as part of the deal. Cannafull manufactures CBD skincare products while Ascend Skincare supplies three CBD-based face serums.

----------

Directa Plus PLC - graphene nanoplatelets supplier - Granted EU patent for company's G+ pristine graphene nanoplatelets, aimed at boosting the performance of rubber-based shoe outsoles. Following the grant of the patent, Directa Plus's intellectual property portfolio will comprise 18 patent families with 72 patents granted and 25 patents pending. Chief Executive and Founder Giulio Cesareo says: "This EU patent will reinforce our position in the fast-growing market for technical footwear, attracting the attention of the major consumer product players."

----------

WANdisco PLC - Sheffield-based data-management software company - Secures a USD3.3 million three-year license contract with an unnamed "large North American multinational investment bank" for the use of LiveData Migrator. WANdisco's revenue share will be 50% of the license under its long-standing original equipment manufacturer agreement with IBM. Following the contract win, management now expects financial year 2021 revenue to be "meaningfully ahead" of current market estimates.

----------

Marlowe PLC - London-based safety and regulatory compliance services and software - Buys e-learning provider Skill Boosters for an initial payment of GBP5.5 million with a growth-based contingent consideration expected to be around GBP2.5 million. Skill Boosters is described as an equality, diversity and inclusion e-learning course provider. Marlowe notes Skill Boosters will offer "attractive cross-sell and technology synergies with Marlowe's compliance software activities, of which eLearning forms a key part".

----------

Kistos PLC - investor in low-carbon energy assets, including in Dutch North Sea - Confirms interest in buying some of TotalEnergies SE's West Shetland gas assets. Following press speculation, Kistos says the potential purchase is in keeping with its stated strategy of growth through acquisition and that it would be funded using the company's existing cash reserves.

----------

By Will Paige; willpaige@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
31 Mar 2023 16:39

TRADING UPDATES: FireAngel signs with British Gas; Shanta pours gold

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
1 Mar 2023 20:09

TRADING UPDATES: Ediston signs 10-year lease with Marks & Spencer

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
1 Mar 2023 14:26

ValiRx incorporates new wholly-owned lab subsidiary

(Sharecast News) - Life science company ValiRx announced the incorporation of a new wholly-owned subsidiary, Inaphaea BioLabs, on Wednesday.

Read more
3 Feb 2023 13:41

TRADING UPDATES: Somero revenue short of outlook; SigmaRoc optimistic

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
26 Jan 2023 15:44

UK shareholder meetings calendar - next 7 days

Friday 27 January 
Avon Protection PLCAGM
Henderson Far East Income LtdAGM
Ixico PLCAGM
NB Global Monthly Income Fund LtdEGM re proposed managed wind-down
On The Beach Group PLCAGM
Pathfinder Minerals PLCGM re capital raise
Serica Energy PLCGM re consideration shares approval
Treatt PLCAGM
Monday 30 January 
Bluebird Merchant Ventures LtdAGM
Contango Holdings PLCAGM
Hollywood Bowl Group PLCAGM
SkinBioTherapeutics PLCGM re annual report review
Starwood European Real Estate Finance LtdEGM re capital return 
Webis Holdings PLCAGM
Tuesday 31 January 
Hydrogen Future Industries PLCAGM
Mobile Streams PLCAGM
Residential Secure Income PLCAGM (TBC)
Star Phoenix Group LtdGM re removal and appointment of auditor
Team PLCAGM
Yamana Gold IncSGM re transaction with Agnico Eagle Mines Ltd and Pan American Silver Corp
Zamaz PLCAGM
Wednesday 1 February 
Baronsmead Second Venture Trust PLCAGM
Baronsmead Venture Trust PLCAGM
Capricorn Energy PLCGM re directors removal and appointment of new directors
Catalyst Media GroupAGM
Hyve Group PLCAGM
Imperial Brands PLCAGM
Premier Miton Group PLCAGM
Renew Holdings PLCAGM
Schroder Asia Pacific Fund PLCAGM
Thursday 2 February 
abrdn Equity Income Trust PLCAGM
Alteration Earth PLCAGM
Baillie Gifford European Growth Trust PLCAGM
JPMorgan Indian Investment Trust PLCAGM
Sage Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Tectonic Gold PLCAGM
ValiRx PLCGM re fundraising
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
17 Jan 2023 21:40

TRADING UPDATES: Future Metals in JV; Gunsynd sells stake in investee

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
13 Jan 2023 13:31

IN BRIEF: ValiRx seeks up to GBP1.5 million for new research facility

ValiRx PLC - Hatfield Heath, England-based life sciences company focused on early-stage cancer therapeutics and women's health - Raises GBP1 million from placing of 9.1 million shares at 11 pence each. Also will raise up to GBP500,000 more from a broker offer to retail investors at the same price. Turner Pope Investments Ltd will run the broker offer. Every four shares in the placing and retail offer come with a warrant to buy another new share at 14p over the next three years. Calls February 2 general meeting to approve the fund raise. Currently has a GBP10.1 million market capitalisation.

Read more
6 Dec 2022 11:31

ValiRx shares fall on test extension, but optimistic of other assets

(Alliance News) - ValiRx PLC on Tuesday saw shares drop, after extending its evaluation agreement with Hokkaido University to conduct further experimental testing.

Read more
24 Oct 2022 12:47

ValiRx forms new majority-owned breast cancer subsidiary

(Sharecast News) - Women's health and cancer therapeutics company ValiRx announced the formation of a new partially-owned subsidiary, Cytolytix, on Monday, which had signed an intellectual property licence agreement with King's College London (KCL).

Read more
24 Oct 2022 10:05

ValiRx teams with King's College London for cancer project

(Alliance News) - ValiRx PLC on Monday said it is making progress on its goal to introduce new academic projects into its portfolio, after launching subsidiary company Cytolytix Ltd and signing a licence agreement with King's College London.

Read more
8 Sep 2022 11:47

IN BRIEF: ValiRx shares up on new interim chief scientific officer

ValiRx PLC - Nuneaton, England-based drug development company - Appoints Catherine Tralau-Stewart as interim chief scientific officer. Says she has experience working across leading pharmaceutical companies and academic groups. Tralau-Stewart will review new, incoming science; enhance the progress of existing projects; and influence the overall strategic scientific direction of the company, ValiRx adds. Chief Executive Suzy Dilly comments: "I'm looking forward to having another in-house scientist with whom to share ideas and to develop and deliver upon our strategic ambitions. Cathy's wealth of experience in exactly the areas in which we wish to progress, makes her an excellent choice for this role."

Read more
31 Aug 2022 13:51

EARNINGS UPDATES: Windward widens loss as operating expenses rise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
13 Jul 2022 14:44

IN BRIEF: ValiRx shares jump on breast cancer drug candidate progress

ValiRx PLC - Nuneaton, England-based drug development company - Completes the evaluation of the impact of a peptide drug candidate against triple negative breast cancer. Evaluation concludes there is "good evidence" of biological activity and a "strong" rationale for further development. Adds that the drug candidate was investigated over nine months. Tests also demonstrate promising data on ovarian cancer cells, in addition to the targeted breast cancer cells. As a result, ValiRx has notified the academic team and intellectual property & licensing team at King's College London that it wants to proceed to full in-licensing.

Read more
5 Jul 2022 15:51

IN BRIEF:ValiRx gains GBP1.0 million from Turner Pope broker option

ValiRx PLC - Nuneaton, England-based drug development company - Announces that the broker option granted to Turner Pope Investments Ltd has been fully subscribed and raises GBP1.0 million before expenses.

Read more
30 Jun 2022 17:31

TRADING UPDATES: M&C Saatchi expects to deliver on annual profit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.